Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
44M
-
Shares change
-
+6.78M
-
Total reported value, excl. options
-
$959M
-
Value change
-
+$148M
-
Put/Call ratio
-
0.13
-
Number of buys
-
60
-
Number of sells
-
-63
-
Price
-
$21.80
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q1 2018
155 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q1 2018.
NovoCure Ltd - Common Stock (NVCR) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44M shares
of 112M outstanding shares and own 39.3% of the company stock.
Largest 10 shareholders include FMR LLC (6.98M shares), VANGUARD GROUP INC (4.83M shares), BlackRock Inc. (3.77M shares), BAILLIE GIFFORD & CO (2.75M shares), FARALLON CAPITAL MANAGEMENT LLC (1.85M shares), StepStone Group LP (1.37M shares), WADDELL & REED FINANCIAL INC (1.31M shares), CITADEL ADVISORS LLC (1.19M shares), Tamarack Advisers, LP (1.12M shares), and STATE STREET CORP (1.11M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.